Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Current Deferred Revenue (2020 - 2024)

Historic Current Deferred Revenue for Allogene Therapeutics (ALLO) over the last 5 years, with Q1 2024 value amounting to $86000.0.

  • Allogene Therapeutics' Current Deferred Revenue changed 0.0% to $86000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $86000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $86000.0 for FY2023, which is 947.37% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Current Deferred Revenue of $86000.0 as of Q1 2024, which was down 0.0% from $86000.0 recorded in Q4 2023.
  • Allogene Therapeutics' Current Deferred Revenue's 5-year high stood at $39.0 million during Q4 2020, with a 5-year trough of $86000.0 in Q1 2023.
  • Its 5-year average for Current Deferred Revenue is $2.9 million, with a median of $101500.0 in 2022.
  • In the last 5 years, Allogene Therapeutics' Current Deferred Revenue crashed by 9959.99% in 2021 and then changed by 0.0% in 2024.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Current Deferred Revenue stood at $39.0 million in 2020, then crashed by 99.6% to $156000.0 in 2021, then crashed by 39.1% to $95000.0 in 2022, then fell by 9.47% to $86000.0 in 2023, then changed by 0.0% to $86000.0 in 2024.
  • Its Current Deferred Revenue stands at $86000.0 for Q1 2024, versus $86000.0 for Q4 2023 and $86000.0 for Q3 2023.